ArticleBMJ open diabetes research & care2025

Evaluating GLP-1 receptor agonists versus metformin as first-line therapy for reducing dementia risk in type 2 diabetes.

Mingyang Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.